Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$26.31M, compared with -$13.28M a year earlier. Trailing-twelve-month EBITDA was -$67.53M.
Context
- EBITDA amounted to 93.4% of revenue in FY2025, up 37.4 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of -$80.43M (-28.2%) for the fiscal year ending Dec 2026, a slowdown from the +18.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.31M-30.6% QoQ
- Last fiscal yearDec 2025
- -$62.76M+18.9% YoY
- LTMMar 2026
- -$67.53M-3.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -98.2% | -229.8% | -131.7 pp |
| 1 year | +18.9% | -28.2% | -47.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (62.76M) USD
- Year-over-year change
- +18.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (62.76M) | +18.9% |
| FY2024 | 2024-12-31 | (77.4M) | -220.3% |
| FY2023 | 2023-12-31 | (24.17M) | -259.3% |
| FY2022 | 2022-12-31 | 15.17M | +107.6% |
| FY2021 | 2021-12-31 | (199.81M) | — |
EBITDA vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.7% is the 5th highest of 10, against a peer median of -30.1%.
- EBITDA amounts to 148.9% of revenue for ARCT, versus a peer median of 201.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $160.85M USD | +305.5% | — | 84.0% | |
| LTM Mar 2026 | -$42.13M USD | -107.6% | — | 7.1% | |
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$53.46M USD | -44.4% | — | — | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$81.94M USD | +12.2% | — | — | |
| LTM Mar 2026 | -€90.14M EUR | -119.6% | — | 57.7% | |
| LTM Mar 2026 | -$179.89M USD | -30.1% | — | — | |
| LTM Mar 2026 | -$194.47M USD | +21.0% | — | — | |
| LTM Mar 2026 | -$438.52M USD | +24.4% | — | 669.6% | |
| Peer median (excluding ARCT) | — | -30.1% | — | 201.5% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.36M | 205.76M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.03M |
| Gross Profit | 12.36M | 205.76M | 157.75M | 138.39M | 64.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| Research & Development | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| Selling, General & Admin | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| Operating Expenses | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| EBITDA | (199.81M) | 15.17M | (24.17M) | (77.4M) | (62.76M) |
| EBITDA Margin | -1616.7% | 7.4% | -15.3% | -55.9% | -93.4% |
| Operating Income | (202.85M) | 12.18M | (78.21M) | (95.67M) | (74.96M) |
| Operating Margin | -1641.3% | 5.9% | -49.6% | -69.1% | -111.5% |
| Interest Income | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 2.67M | 3M | 767K | 0 | 0 |
| Other Income / Expenses | (822K) | (1.53M) | 50.32M | 14.72M | 9.17M |
| Income Before Tax | (203.67M) | 10.64M | (27.89M) | (80.95M) | (65.78M) |
| Pre-Tax Margin | -1648.0% | 5.2% | -17.7% | -58.5% | -97.9% |
| Income Tax Expense | 0 | 1.3M | 1.84M | (4K) | 0 |
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Net Margin | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (Basic) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| EPS (Diluted) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| Weighted Avg Shares | 26.32M | 26.45M | 26.63M | 27M | 27.39M |
| Weighted Avg Shares (Diluted) | 26.32M | 27.09M | 26.63M | 27M | 27.39M |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.